Eurofins bioskin GmbH — Clinical Trial Site

22 Registered trials

4 Currently recruiting

Organisation

Eurofins bioskin GmbH

Location

Hamburg, Germany

Identifier

ORG-100039569

Address

Messberg 4, Hamburg-Altstadt, 20095, Germany

Departments

#6002; Pruefzentrum
3115
9177: Eurofins bioskin GmbH
Eurofin Bisoskin GmbH
Eurofins bioskin GmbH
n.a.
N/A
NA
Research Center Dermatology
Research Center for Dermatology

Clinical trials at this site (22)

Search interface

A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and fema… Ended

2024-514762-39-00 Neurodermatitis 5 2025-03-03
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted

2025-521503-43-00 Atopic dermatitis 4 2026-02-12
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended

2025-522446-51-00 Plaque psoriasis 3 2025-10-17
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended

2024-511225-64-00 Alopecia areata 4 2024-09-18
Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis Ended

2023-509079-18-00 Plaque Psoriasis 3 2024-07-22
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
Evaluation of irritation potential of topical formulations on intact skin Ended

2024-511826-29-00 Dermal tolerability test: Testing for non-specific, loc 3 2024-06-20
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in com… Ended

2023-507241-28-00 Test of vasocontriction properties for classification o 3 2024-02-26
A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adult… Ended

2023-507393-40-00 psoriasis vulgaris 3 2023-12-12
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss. Ended

2023-504421-39-00 Androgenetic Alopecia 5 2023-11-21